pubmed.ncbi.nlm.nih.gov

Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy - PubMed

  • ️Sat Jan 01 2022

Review

Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy

Caitlyn Smith et al. World J Gastroenterol. 2022.

Abstract

Pancreatic ductal adenocarcinoma is one of the most aggressive and lethal cancers. Surgical resection is the only curable treatment option, but it is available for only a small fraction of patients at the time of diagnosis. With current therapeutic regimens, the average 5-year survival rate is less than 10% in pancreatic cancer patients. Immunotherapy has emerged as one of the most promising treatment options for multiple solid tumors of advanced stage. However, its clinical efficacy is suboptimal in most clinical trials on pancreatic cancer. Current studies have suggested that the tumor microenvironment is likely the underlying barrier affecting immunotherapy drug efficacy in pancreatic cancer. In this review, we discuss the role of the tumor microenvironment in pancreatic cancer and the latest advances in immunotherapy on pancreatic cancer.

Keywords: Chemotherapy; Clinical trial; Immunotherapy; Pancreatic ductal adenocarcinoma; Treatment; Tumor microenvironment.

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declare no competing interests in this study.

Figures

Figure 1
Figure 1

Pancreatic ductal adenocarcinoma with an associated tumor microenvironment. Please note the desmoplastic stromal reaction surrounding the tumor glands, decreased stromal vascularization, and scattered infiltrating inflammatory cells (HE stain, 200 x).

Similar articles

Cited by

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7–33. - PubMed
    1. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271–289. - PubMed
    1. Porta M, Fabregat X, Malats N, Guarner L, Carrato A, de Miguel A, Ruiz L, Jariod M, Costafreda S, Coll S, Alguacil J, Corominas JM, Solà R, Salas A, Real FX. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol. 2005;7:189–197. - PubMed
    1. De Souza A, Khawaja KI, Masud F, Saif MW. Metformin and pancreatic cancer: Is there a role? Cancer Chemother Pharmacol. 2016;77:235–242. - PubMed
    1. Corbo V, Tortora G, Scarpa A. Molecular pathology of pancreatic cancer: from bench-to-bedside translation. Curr Drug Targets. 2012;13:744–752. - PMC - PubMed

Publication types

MeSH terms